首个产品上市收入855万,加科思去年亏损减少

动脉网
Mar 12

加科思药业2025年实现首个产品上市,即KRAS G12C抑制剂戈来雷塞,并确认收入855万元。全年总收入为5350万元,主要来自对外许可协议;亏损减少至1.46亿元,研发开支达1.89亿元。戈来雷塞已纳入国家医保目录,并与SHP2抑制剂联合用于非小细胞肺癌治疗的Ⅲ期临床试验正在开展。此外,口服小分子pan-KRAS抑制剂JAB-23E73在中国和美国进行临床研究,与阿斯利康达成20.15亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10